BACKGROUND: Accurate estimates of survival are indispensable for cardiologists, clinical geneticists, and genetic counselors dealing with families with an inherited cardiac disease. However, a bias towards a more severe disease with a worse outcome in the first publications may not accurately represent the actual survival forecast. We, therefore, evaluated the effect of ascertainment bias on survival in 3 different inherited cardiac diseases (idiopathic ventricular fibrillation, SCN5A overlap syndrome, and arrhythmogenic cardiomyopathy) caused by a founder mutation.
S
ince the 1990s, the molecular genetic basis for many inherited diseases has been elucidated. Once the novel causative gene (mutation) is discovered in patients, the first publications in established medical journals contained the clinical and mortality data of the mutation-positive patients that led to the gene/mutation discovery. Not surprisingly, the patients and families described in these gene discovery publications often comprise severely affected patients and relatives in whom gene identification strategies were promising and eventually turned out to be successful. Severely affected families are more likely to come to the attention of specialized cardiogenetic clinics and to be selected for studies trying to discover the underlying genetic effect. Therefore, the genotype-phenotype associations in general, and survival forecasts in particular, could be subject to ascertainment bias.
In the years following the initial identification of the causative gene, genetic testing of other probands and relatives can be performed (genetic cascade screening) and subsequently new families and relatives with the same gene defect are detected. However, extended data on these newly identified probands and their mutation-positive relatives may never be submitted or published. This is because the publication impact of an already published disease-susceptibility gene/mutation may be deemed too low by the authors or the journal or because cascade screening studies are not performed, because of poor accessibility to genetic services in some countries, for example. This may lead to a persistence of the effect of the ascertainment bias on risk estimates in literature. As a consequence, a possible overestimation of the risks in gene/mutation-positive subjects is maintained in clinical practice.
This undesirable and misleading effect of ascertainment bias on phenotypic characteristics in patients with an inherited disease has been observed previously in literature. For example, in initial studies on hypertrophic cardiomyopathy or Brugada syndrome, the annual mortality and event rates appeared much higher than in later, larger studies with more unselected patients.
1,2 The occurrence of ascertainment bias has also been reported for risk estimates associated with inherited cancer syndromes. 3, 4 We hypothesized that probands and their mutationpositive relatives described in the original gene discovery publications represent a biased cohort with more disease-related mortality because gene or mutation discovery was most promising in severely affected patients and families. To examine the effect of this ascertainment bias on mortality directly, and in detail, we compared median age of survival of probands, and mutation-positive relatives at the moment of the discovery/publication of the genetic defect (ie, the original cohort) with the median age of survival in the same cohort extended with data derived from subsequently newly detected probands and mutation-positive relatives (ie, the extended cohort) after 2 to 10 years of ongoing genetic testing. We did this in 3 different autosomal dominantly inherited cardiac diseases caused by a founder mutation: DPP6-associated idiopathic ventricular fibrillation (IVF), SCN5A overlap syndrome, and PLN-R14del-mediated arrhythmogenic cardiomyopathy (ACM). This process of genetic testing and genetic cascade screening of probands and relatives is incorporated into the Dutch health care system and allowed us to perform this unique study, which for the first time precisely quantifies the negative effect of ascertainment bias on mortality.
METHODS
The data, analytic methods, and study materials can be made available to other researchers for purposes of reproducing the results or replicating the procedure, but only in a derived version where the anonymity of the study subjects can be guaranteed. Patients gave informed consent, and the study was approved by the institutional ethical committee.
The methods are available in the Data Supplement.
RESULTS

IVF Families
In 2008, haplotype sharing analyses revealed a risk haplotype harboring the DPP6 gene on chromosome 7q36 in 10 families with IVF. 5 In these affected DPP6 haplotype-positive subjects (n=60 haplotype-positive subjects from 10 families), the median age of survival was 44.6 years (95% CI, 36.8-52.4 years) in 2008 which increased to 68.2 years (95% CI, 64.6-71.7 years; P<0.001) in 2012 when new families and haplotypepositive relatives were added to our analyses (n=235 haplotype-positive subjects from 20 families; Table; 
SCN5A-Overlap Syndrome Family
In 1999, linkage analyses in a large pedigree with a long-QT and Brugada overlap syndrome revealed linkage to SCN5A. 6 After DNA sequencing, the p.1795insAsp mutation syndrome was detected in 86 subjects. In the subsequent 10 years, genetic cascade screening of relatives in this extended family identified 109 additional (including obligate and putative) mutation-positive relatives. The median age of survival increased from 56. 
ACM Families
In 2010, a cohort of unrelated probands diagnosed with ACM (either dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy) was analyzed for mutations in PLN-encoded phospholamban. 7 A 3 bp deletion (c.40_42delAGA; p.R14del) was identified in 15% of the dilated cardiomyopathy-index patients and 12% of the arrhythmogenic right ventricular cardiomyopathy-index patients. The median age of survival increased from 63. 
DISCUSSION
This study reveals that the median age of survival in 3 different genetically mediated cardiac diseases significantly increased once cascade screening and genetic testing of new families began in the years following the sentinel disease-gene discovery publication. This is important to know because preventive/treatment options and cardiac screening regimes are often based on data from this first disease-gene discovery publications and does not always accurately reflect the actual disease prognosis in newly discovered patients and relatives detected by genetic testing.
For all inherited cardiomyopathies and primary arrhythmia syndromes, there is international consensus that genetic testing is useful and cost effective because the mutation can sometimes guide clinical management of the proband, but more importantly can correctly identify at risk relatives in whom sudden cardiac death (SCD) can be prevented and dismiss mutation negative relatives from cardiological follow-up. Genetic cascade screening is, therefore, recommended whenever possible. 8 In the Netherlands, the health care system reimburses genetic screening and genetic counseling. In all university hospitals, cardiogenetic teams are available while distances to those hospitals are relatively short. We are, therefore, in the position to perform this study to show the effect of genetic screening over the years on survival rates, since genetic counseling is readily available to all citizens. Because we think that genetic testing will also be more readily available in other countries, our data are relevant to other populations as well and may serve as a proof of principle for all inherited cardiac diseases suggesting an initial overestimation of disease severity, especially in first publications.
All studied diseases have an increased risk of SCD and, therefore, increased mortality. However, the phenotype can be broader, and disease-specific advices towards prevention and treatment are given. The phenotype of DPP6 haplotype carriers is characterized by IVF at young age, without prior symptoms. Currently, there is no specific risk stratification for VF based on clinical risk factors. Treatment consists of implantation of an implantable cardioverter defibrillator in all carriers of the risk haplotype between 20 and 55 years. 5 The SCN5A-p.1795insAsp overlap syndrome family originally came to our attention because of the specific phenotype of bradycardia-dependent QT prolongation, sinus node dysfunction, conduction abnormalities, and the high incidence of nocturnal sudden death. Bradyarrhythmias are believed to be an important cause of death, and hence implantation of a pacemaker can also prevent SCD. Furthermore, mutation-positive subjects are advised to avoid drugs associated with long-QT syn- drome and Brugada syndrome. 9,10 PLN-p.Arg14del positive patients can have ACM with abnormalities of the left and right ventricle. Treatment consists of medication and implantable cardioverter defibrillator implantation in case of arrythmias or heart failure, or cardiac transplantation in the most severe cases. 7, 11 Our most extensively analyzed cardiac disease in this study, with the most pronounced difference in median age of survival, is DPP6-associated IVF. The median age of survival gradually increased by ≈25 years in just 4 years of additional follow-up and extension of the original cohort. In 2008, families with a distinct severe phenotype of VF or SCD without a known cause were selected for research purposes. The pedigrees of these families consisted of probands with often multiple relatives who suffered from SCD. In these families, the risk haplotype, including the DPP6 gene, was identified. In the following years, new both alive and asymptomatic family members were tested and new probands and their relatives with the DPP6 risk haplotype were identified. Figure 1B shows the gradual increase in the median age of survival over time in DPP6-associated IVF with the inclusions of more risk haplotype-positive subjects over the years. It also clearly demonstrates that inclusion of new families, evaluated because of cardiac events, led to a small decrease in the median age of survival. Subsequently, after testing asymptomatic relatives, the median age of survival increased. After a cer- tain number of DPP6 risk haplotype-positive subjects was identified in these families, (n≈168, Figure 1B) , a plateau was reached and the inclusion of new probands and relatives no longer influenced the median age of survival, suggesting that the median age of survival at the plateau most likely represents the true and unbiased mortality risk for this genetic disease. This genetic heart disease quantitatively illustrates just how large the effect of ascertainment bias can be on the median age of survival over time, because of the selection of severely affected families with many cases of VF or SCD at a young age at the start of the study, followed by the gradual inclusion of more asymptomatic relatives. The effect of treatment did not influence or bias our analysis because the implantable cardioverter defibrillator registration of VF was used as an end point.
In DPP6-associated IVF, survival was significantly different between males and females in 2008 and 2012. The effect of ascertainment bias in this disease is, therefore, also seen in the gender distribution in the publication cohort from 2008, in which more males were included, while one would expect an equal ratio of males to females in an unselected population of individuals of an autosomal dominantly inherited disease. It is, therefore, important to acknowledge that in inherited diseases where the expression of the disease is different between males and females, the ascertainment bias can also be shown by an unequal gender distribution.
Furthermore, we looked at the effect of the probands on the age of survival in DPP6-associated IVF. Our data cannot be generalized to probands in general because we only compared mortality of the entire gene positive population-both probands and relatives-at first gene discovery and later in time. Of course, one might think that the ascertainment bias also holds for probands at first gene discovery compared with probands later in time. We compared the median age of survival of the first 10 probands from the original publication compared with 10 additional probands from the extended cohort. There was no significant difference in median age of survival (data not shown). In DPP6-associated IVF the difference in median age of survival between the cohorts is, therefore, believed not to be because of a younger event age in the probands but a higher number of events in the first described families. The first studied families had more SCD events compared with the families detected later on. Exclusion of the probands from our analyses also did not change the results, indicating that a more severe phenotype in probands is not a factor in the difference in age of survival over time in this particular disease.
In the large SCN5A-p.1795insAsp overlap syndrome family, the median age of survival increased by more than a decade. In this group, the ratio of males and females was not statistically different between the original cohort compared with the extended cohort.
Because pacemaker implantation helps to prevent sudden death, we censored all living p.1795Asp positive patients at the moment of DNA diagnostics or pacemaker implantation. If patients had died before DNA diagnostics was performed (obligate carriers) or had received a pacemaker (based on their phenotype) before DNA diagnostics was performed, they were also censored. Therefore, the effect of treatment did not or minimally influence or bias the analyses. This moment of censoring resulted in relatively less additional patient-years (follow-up starting at birth) in the extended cohort compared with the original cohort and added relatively few events to the survival analysis. Despite this, the median age of survival still increased by >13 years.
In our most recently discovered founder mutation, PLN-p.Arg14del-mediated ACM, the median age of survival has increased by just 2 years, despite a large number of additional mutation-positive families and family members in the 2 years after the gene discovery. The ratio of males and females was not statistically different. This suggests less ascertainment bias at the beginning of the study; a large group of dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy probands was selected, purely on their phenotype and not so much on their family history of SCD. Because we did not take the treatment of our patients into account, timely treatment of PLN-p. Arg14del positive patients could have influenced the median age of survival at the end of our study.
The inclusion of alive and asymptomatic subjects, who are able to undergo DNA diagnostics, could result in a bias towards alive/surviving subjects. However, for the analyses in all 3 inherited diseases, any first degree relative of an established mutation-positive relative with SCD ≤50 years of age was assumed to have been mutation positive (50% pretest probability without testing).
Because we did not perform additional genetic testing, we cannot exclude that multiple genetic hits are the underlying cause of the differences in phenotypes between the initial affected families and the newly acquainted families and underlie the ascertainment bias.
CONCLUSIONS
To our knowledge, we hereby clearly, and for the first time in a direct comparison, elucidate and quantitate the effect of ascertainment bias on the prognosis in large groups of patients with an inherited cardiac disease. Clearly, this could have a significant impact on the information physicians give to their patients and potentially on the treatment choices made in some families (eg, pacemaker or implantable cardioverter defibrillator implantation). Our results might serve as a proof of principle for all inherited cardiac diseases. They suggest an initial overestimation of disease severity, especially in first publications. It is, therefore, important that clinical follow-up data of larger (genetically tested) inherited disease cohorts will be collected and published to enable physicians to give patients more accurate information on their disease prognosis.
